Nanotechnology Now - Press Release: Abraxis BioScience to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference

Home > Press > Abraxis BioScience to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference

Abstract:
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that Lonnie Moulder, President and Chief Executive Officer, will present a company overview at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009 at 2:40 p.m. EDT, at The New York Palace Hotel in New York City.

Abraxis BioScience to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference

Los Angeles, CA | Posted on May 5th, 2009

A live webcast of the presentation will be available in the Investor Relations section of the company's website at www.abraxisbio.com as well as www.veracast.com/webcasts/bas/healthcare09/id72210376.cfm. The webcast will be archived and accessible at both locations for at least 14 days.

####

About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 36 countries. The company continues to expand the nab® platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.

For more information, please click here

Contacts:
Investor & Media Inquiries
Maili Bergman
Director Investor Relations & Corporate Communications
310-883-1300

or
PondelWilkinson Inc.
Rob Whetstone
310-279-5963

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: